CurrentCentenePolicy MC.CP.MP.184

Home Ventilators

Medical necessity criteria and coverage guidance for noninvasive and invasive home ventilators for Centene-affiliated Health Plans, including initial and continued use, indications, and backup ventilator rules; applies to Medicare health plans with references to non‑Medicare criteria elsewhere.

Policy Summary

PayerCentene

PolicyHome Ventilators

Policy CodePolicy MC.CP.MP.184

Change TypeCoding updatereference review

Effective Date

Next Review Date

Key ActionObtain prior authorization with documentation of diagnosis, qualifying physiologic measurements, and device usage (average ≥4 hours/24 hr) to support initial and continued coverage.

SourceLink

POLICY UPDATE CHANGES

CPT code E0468 was added to the policy coding implications.

References were reviewed and updated during the annual review.

3 monthsinitial certification period

≥4 hrs/24 hrmin avg daily use

≥45 mm HgPaCO2 threshold (restrictive)

≥52 mm HgPaCO2 threshold (COPD)

E0465–E0468referenced HCPCS

Coverage Criteria for Home Ventilators

Medical necessity criteria

Covered when ALL of the following are met for initial requests (first three months) and continuation criteria thereafter as specified:

Initial - Restrictive Thoracic Disorders / Neuromuscular Disease: Documentation of a neuromuscular disease (e.g., amyotrophic lateral sclerosis) or a severe thoracic cage abnormality AND one of the following measured while the member was stable (not in acute respiratory failure): (a) PaCO2 ≥ 45 mm Hg measured while awake and breathing room air or prescribed oxygen; (b) sleep oximetry demonstrating O2 saturation ≤ 88% for at least five minutes while breathing prescribed O2; (c) if neuromuscular disease is present, maximal inspiratory pressure (MIP) < 60 cm H2O or forced vital capacity (FVC) < 50% predicted.see children

Physiologic measurements must be obtained while stable (not in acute respiratory failure).

Initial - Additional Requirements: Documentation supports both: (a) the member could not be appropriately treated with a respiratory assist device (RAD); and (b) the noninvasive home ventilator will not be used to provide RAD or CPAP therapy (i.e., will be used to provide average volume assured pressure support).

COPD should not contribute significantly to pulmonary limitation for restrictive/neuromuscular indication.

Policy Summary

PayerCentene

PolicyHome Ventilators

Policy CodePolicy MC.CP.MP.184

Change TypeCoding updatereference review

Effective Date

Next Review Date

Key ActionObtain prior authorization with documentation of diagnosis, qualifying physiologic measurements, and device usage (average ≥4 hours/24 hr) to support initial and continued coverage.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

The policy specifies that the noninvasive home ventilator (NHV) must be used for its intended ventilatory function and not as a substitute for simpler positive airway pressure therapies. Specifically, documentation must show that the NHV will not be used to provide respiratory assist device (RAD) or continuous positive airway pressure (CPAP) therapy and instead will be used to provide average volume‑assured pressure support. This requirement is part of the initial coverage criteria and must be confirmed both for restrictive/neuromuscular indications and for COPD indications prior to approval for the initial three‑month certification period.

For COPD, the policy additionally requires that sleep apnea and treatment with CPAP be considered and ruled out before initiating NHV; if CPAP or RAD would appropriately treat the patient, NHV is not indicated. Measurements and documentation used to justify NHV (for example PaCO2 thresholds, sleep oximetry, or MIP/FVC when neuromuscular disease is present) must be obtained while the member is stable (not in acute respiratory failure).

The NHV is considered not medically necessary when a RAD or CPAP device would appropriately treat the condition, or when required physiologic criteria and supporting documentation are absent. Examples include missing qualifying PaCO2 measurements, absent sleep oximetry demonstrating O2 saturation ≤ 88% for ≥ five minutes, or lack of MIP/FVC results when neuromuscular disease is claimed.

For COPD indications, NHV is not medically necessary unless the record documents a baseline arterial PaCO2 ≥ 52 mm Hg measured while awake and breathing prescribed FiO2, and evidence that CPAP and/or RAD are not appropriate. Requests that do not show CPAP has been considered and ruled out (or documentation explaining why formal sleep testing is unnecessary because sleep apnea is not the predominant cause of hypercapnia) may be denied.

DME Medical Necessity

DME medical necessity

DME-specific medical necessity criteria mirror clinical criteria for NHV vs RAD/CPAP and include usage requirements for continued coverage.

Initial NHV (restrictive/neuromuscular): Diagnosis of neuromuscular disease or severe thoracic cage abnormality AND qualifying physiologic measurements while stable (PaCO2 ≥ 45 mm Hg OR sleep oximetry O2 saturation ≤ 88% for ≥ 5 minutes OR if neuromuscular disease present MIP < 60 cm H2O or FVC < 50% predicted) AND documentation that RAD is not appropriate AND confirmation that the NHV will not be used to provide RAD or CPAP (will be used to provide average volume assured pressure support).

Measurements must be while stable (not in acute respiratory failure).

Initial NHV (COPD): PaCO2 ≥ 52 mm Hg measured while awake and breathing baseline and prescribed FiO2; CPAP/sleep apnea evaluated and ruled out as the predominant cause of hypercapnia; documentation that RAD is inappropriate; and confirmation NHV will not be used for RAD/CPAP functions.PaCO2 ≥ 52 mm Hg

Formal sleep testing not required if records demonstrate sleep apnea is not the predominant cause of hypercapnia.

Continued DME coverage: Device usage averages ≥ 4 hours per 24-hour period AND documentation of ongoing benefit from the device AND confirmation the device is not being used to provide RAD or CPAP therapy.>= 4 hours/24 hr

Required for ongoing coverage and prior authorization renewal.

Coding and Clinical Thresholds

Referenced HCPCS CodesHCPCS

E0465	Home ventilator, any type, used with invasive interface (e.g., tracheostomy tube)
E0466	Home ventilator, any type, used with noninvasive interface (e.g., mask, chest shell)
E0467	Home ventilator, multi-function respiratory device, also performs functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation; includes all accessories
E0468	Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation; includes all accessories

PaCO2 thresholds

Restrictive thoracic disordersPaCO2 ≥ 45 mm Hg measured while awake and breathing room air or prescribed oxygen

COPD indicationPaCO2 ≥ 52 mm Hg measured while awake and breathing baseline and prescribed FiO2

Measurement conditionPaCO2 values must be obtained while the member is stable (not in acute respiratory failure)

Sleep oximetry

Required sleep oximetry thresholdO2 saturation ≤ 88% for at least five minutes while breathing prescribed O2

Use contextApplies as one qualifying criterion for restrictive thoracic disorder indication

Documentation noteMeasurements must be obtained while the member is stable (not in acute respiratory failure)

Usage

Minimum average daily useDevice used at least an average of 4 hours per 24‑hour period

PurposeRequired for continued coverage after the initial three‑month certification period

DocumentationOngoing benefit from use must also be documented alongside usage data

MIP / FVC thresholds for neuromuscular disease

Maximal inspiratory pressure (MIP)MIP < 60 cm H2O qualifies when neuromuscular disease is present

Forced vital capacity (FVC)FVC < 50% predicted qualifies when neuromuscular disease is present

ContextMIP/FVC criteria apply as qualifying physiologic measurements for restrictive/neuromuscular indications

Provider Requirements and Actions

Prior Authorization

Prior Authorization and Documentation Required

Prior authorization is required for initial and continuation requests. Include supporting documentation demonstrating medical necessity for the requested period of noninvasive home ventilator use.

Applies to initial (first 3 months) and continued use beyond initial certification period
Include clinical measurements obtained while member was stable (not in acute respiratory failure)

Documentation Required

Trial of CPAP/BiPAP — Documented Attempt or Rationale Required

A trial of CPAP or BiPAP (or other respiratory assist device) must be considered and documented as inadequate or not appropriate prior to initiating a noninvasive home ventilator for conditions where obstructive sleep apnea or CPAP-responsive disease could explain hypercapnia or nocturnal desaturation. If CPAP/BiPAP would not address the physiologic abnormality, document the rationale.

Formal sleep testing is not required if the medical record documents that OSA/CSA/CompSA is not the predominant cause of awake hypercapnia or nocturnal desaturation
Document that RAD/CPAP therapy is inadequate or that the ventilator will not be used to provide RAD/CPAP (device will provide average volume assured pressure support)

Documentation Required

Required Clinical Documentation

Required clinical documentation must be submitted with prior authorization requests. Include diagnosis, physiologic measurements obtained while the member was stable (not in acute respiratory failure), and device-use evidence.

Primary diagnosis (e.g., neuromuscular disease, severe thoracic cage abnormality, or COPD)
Arterial blood gas with PaCO2 while awake and on prescribed FIO2 or room air (e.g., ≥45 mm Hg for restrictive/neuromuscular indications; ≥52 mm Hg for COPD indication)
Sleep oximetry results if applicable (O2 saturation ≤88% for ≥5 minutes)
If neuromuscular disease: maximal inspiratory pressure <60 cm H2O or FVC <50% predicted
Documentation that RAD/CPAP was considered and is inadequate or inappropriate
For continuation requests: documentation of device use average ≥4 hours per 24-hour period and evidence of ongoing clinical benefit

Denial Risk

Documentation and Clinical Criteria Missing — Denial Risk

If required documentation or clinical criteria are missing, the request is at high risk for denial. Incomplete records that lack the specific physiologic measurements, documentation of CPAP/BiPAP trial or rationale, diagnosis, or evidence of device use for continuation may result in non-coverage.

Missing arterial blood gas or sleep oximetry data
No documentation that CPAP/BiPAP or RAD was considered or shown inadequate
Lack of neuromuscular or thoracic disorder metrics when claimed (MIP, FVC)
No proof of ≥4 hours/day average use or absence of documented ongoing benefit for continuation requests

Definitions

Noninvasive ventilation (NIV) definition

Typical interfacesNasal masks, orofacial masks, full face masks, mouthpieces, nasal pillows, or helmets

Delivery methodNoninvasive delivery of positive pressure to the lungs via external interfaces

Distinguishing noteNIV is provided without an invasive airway (e.g., no tracheostomy or endotracheal tube)

Invasive ventilation definition

Invasive interface examplesTracheostomy tube or endotracheal tube

Delivery methodPositive pressure delivered through an invasive airway interface

Use caseDescribes invasive ventilatory support as distinct from NIV

Noninvasive home ventilator (NHV) definition

Primary capabilityDelivers variable airway pressures within a preset range to reach a targeted volume per breath

Distinction from BiPAPUsed when needs exceed support that BiPAP at optimal settings can provide

Intended useProvides average volume‑assured pressure support rather than functioning as RAD or CPAP

Required Documentation for Authorization and Coverage

Documentation Required

Documentation required for prior authorization and continued coverage

For prior authorization and ongoing coverage, clinical documentation must include the diagnosis, physiologic test results (PaCO2, sleep oximetry, and MIP/FVC when applicable), evidence that RAD/CPAP are not appropriate, baseline FiO2 for COPD measurements, and usage data demonstrating average ≥4 hours per 24‑hour period for continuation.

Diagnosis (e.g., neuromuscular disease or severe thoracic cage abnormality).
PaCO2 measured while awake on baseline/prescribed FiO2 (≥52 mm Hg for COPD when indicated).
Sleep oximetry results (≤88% for ≥5 minutes) when applicable.
MIP <60 cm H2O or FVC <50% predicted if neuromuscular disease present.
Documentation that RAD/CPAP are inappropriate and that NHV will not be used to provide RAD/CPAP.
Usage data and documentation of ongoing benefit for continued coverage (average ≥4 hours/24 hr).

Rental and Purchase Rules for Home Ventilators

HCPCS Code	Description	Rental vs Purchase
E0465	Home ventilator, any type, used with invasive interface (e.g., tracheostomy tube).	Rental or purchase dependent on payer policy and coding rules (refer to payer/DME MAC guidance).
E0466	Home ventilator, any type, used with noninvasive interface (e.g., mask, chest shell).	Rental or purchase dependent on payer policy and coding rules (refer to payer/DME MAC guidance).
E0467	Home ventilator, multi-function respiratory device that may perform oxygen concentration, drug nebulization, aspiration, and cough stimulation; includes accessories.	Rental or purchase dependent on payer policy and coding rules (refer to payer/DME MAC guidance).
E0468	Home ventilator, dual-function respiratory device that also performs cough stimulation; includes accessories.	Rental or purchase dependent on payer policy and coding rules (CPT code E0468 was added to the policy coding implications).

Background

Noninvasive ventilation (NIV) delivers positive pressure support through external interfaces such as nasal or full‑face masks, mouthpieces, or helmets to assist breathing without an invasive airway. Invasive ventilation provides positive pressure through an invasive interface (for example, a tracheostomy tube or endotracheal tube) and is used when long‑term invasive support is required. Home ventilation is preferred when clinically appropriate because it can reduce infections and acute care utilization while supporting patient independence and quality of life. The noninvasive home ventilator (NHV) differs from standard BiPAP by delivering variable airway pressures to achieve a targeted volume per breath and is indicated when BiPAP or RAD at optimal settings are insufficient.

OpenPayer

Home Ventilators

Coverage Criteria for Home Ventilators

DME Medical Necessity

Coding and Clinical Thresholds

Provider Requirements and Actions

Definitions

Required Documentation for Authorization and Coverage

Rental and Purchase Rules for Home Ventilators

Replacement and Device Details

Background

Not Covered

Revision History